Biogen (BIIB)
(Delayed Data from NSDQ)
$232.75 USD
+3.69 (1.61%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $232.62 -0.13 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
BIIB 232.75 +3.69(1.61%)
Will BIIB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
Other News for BIIB
Biogen Completes Acquisition of Human Immunology Biosciences
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth
Biogen, Eisai launch Alzheimer's drug Leqembi in China
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Black Diamond Therapeutics (BDTX) and Biogen (BIIB)
IN BRIEF: Biogen's Leqembi launches in China to treat Alzheimer's